Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Hosaka

Showing results (151-160 of 306) with videos related to

Pageof 31
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 19, 2007
Changes in viral loads of lamivudine-resistant mutants during entecavir therapyFumitaka Suzuki, Yoshiyuki Suzuki, Norio Akuta, et al.
Journal of Medical Virology|May 16, 2012
Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1Norio Akuta, Fumitaka Suzuki, Yuya Seko, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 9, 2014
HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapyTetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, et al.
Journal of Medical Virology|February 27, 2020
Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinomaNorio Akuta, Fumitaka Suzuki, Mariko Kobayashi, et al.
Intervirology|August 22, 2012
Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapyYuya Seko, Norio Akuta, Fumitaka Suzuki, et al.
Journal of Medical Virology|June 20, 2012
Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinomaMakiko Takeyasu, Norio Akuta, Fumitaka Suzuki, et al.
Hepatology Communications|September 17, 2021
Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During EntecavirTetsuya Hosaka, Fumitaka Suzuki, Mariko Kobayashi, et al.
Internal Medicine (Tokyo, Japan)|May 26, 2020
SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver HistopathologyNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|November 8, 2011
[Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure]Norihiro Imai, Kenji Ikeda, Yuya Seko, et al.
Hepatology International|March 20, 2022
Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver diseaseNorio Akuta, Yusuke Kawamura, Fumitaka Suzuki, et al.
Pageof 31

Showing results (151-160 of 306) with videos related to

Sort By:
Pageof 31
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 19, 2007
Changes in viral loads of lamivudine-resistant mutants during entecavir therapyFumitaka Suzuki, Yoshiyuki Suzuki, Norio Akuta, et al.
Journal of Medical Virology|May 16, 2012
Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1Norio Akuta, Fumitaka Suzuki, Yuya Seko, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 9, 2014
HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapyTetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, et al.
Journal of Medical Virology|February 27, 2020
Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinomaNorio Akuta, Fumitaka Suzuki, Mariko Kobayashi, et al.
Intervirology|August 22, 2012
Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapyYuya Seko, Norio Akuta, Fumitaka Suzuki, et al.
Journal of Medical Virology|June 20, 2012
Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinomaMakiko Takeyasu, Norio Akuta, Fumitaka Suzuki, et al.
Hepatology Communications|September 17, 2021
Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During EntecavirTetsuya Hosaka, Fumitaka Suzuki, Mariko Kobayashi, et al.
Internal Medicine (Tokyo, Japan)|May 26, 2020
SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver HistopathologyNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|November 8, 2011
[Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure]Norihiro Imai, Kenji Ikeda, Yuya Seko, et al.
Hepatology International|March 20, 2022
Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver diseaseNorio Akuta, Yusuke Kawamura, Fumitaka Suzuki, et al.
Pageof 31